The Newly Developed CRF1-Receptor Antagonists, NGD 98-2 and NGD 9002, Suppress Acute Stress-Induced Stimulation of Colonic Motor Function and Visceral Hypersensitivity in Rats

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Million, Mulugeta ^a,b,c   Zhao, Jing Fang ^a,c   Luckey, Andrew ^a,c   Czimmer, József ^a,c   Maynard, George D ^d   Kehne, John ^d   Hoffman, Diane C ^d   Taché, Yvette ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d NEUROGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 METHOXY 4 TRIFLUOROMETHOXYPHENYL) [N (1 ETHYL)PROPYL] 3 METHOXY 6 METHYLPYRAZINE 2 AMINE TOSYLATE; 5 (6 ISOPROPYL 2 METHYLAMINOPYRIDIN 3 YL) [N (1 ETHYL)PROPYL] 3 METHOXY 6 METHYLPYRAZINE 2 AMINE HYDROCHLORIDE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; NGD 9002; NGD 98 2; UNCLASSIFIED DRUG; 5 (6 ISOPROPYL 2 METHYLAMINOPYRIDIN 3 YL) (N (1 ETHYL)PROPYL) 3 METHOXY 6 METHYLPYRAZINE 2 AMINE; 5-(6-ISOPROPYL-2-METHYLAMINOPYRIDIN-3-YL)-(N-(1-ETHYL)PROPYL)-3-METHOXY-6-METHYLPYRAZINE-2-AMINE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; N (1 ETHYLPROPYL) (3 METHOXY 5 (2 METHOXY 4 TRIFLUOROMETHOXYPHENYL) 6 METHYL PYRAZIN 2 YL)AMINE; N-(1-ETHYLPROPYL)-(3-METHOXY-5-(2-METHOXY-4-TRIFLUOROMETHOXYPHENYL)-6-METHYL-PYRAZIN-2-YL)AMINE; PYRAZINE DERIVATIVE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANNULATION; COLORECTAL DISEASE; COLORECTAL DISTENSION; CONTROLLED STUDY; DEFECATION; DIARRHEA; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; HYPERSENSITIVITY; INTESTINE FUNCTION; IRRITABLE COLON; MALE; MUSCLE CONTRACTION; NOCICEPTION; NONHUMAN; OROGASTRIC DRUG ADMINISTRATION; RAT; SIGNAL TRANSDUCTION; WATER STRESS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; COLON; DIGESTIVE TRACT INTUBATION; DRUG ANTAGONISM; DRUG EFFECT; HYPERALGESIA; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VISCERA;

ADMINISTRATION, ORAL; ANIMALS; COLON; CORTICOTROPIN-RELEASING HORMONE; DEFECATION; DIARRHEA; DRUG ANTAGONISM; HYPERALGESIA; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; INTUBATION, GASTROINTESTINAL; IRRITABLE BOWEL SYNDROME; MALE; MOLECULAR STRUCTURE; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PHYSIOLOGICAL; VISCERA;

EID: 84883650574     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073749     Document Type: Article

References (63)

1. Vale W, Spiess J, Rivier C, Rivier J, (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and b-endorphin. Science 213: 1394-1397.
2. Bale TL, Vale WW, (2004) CRF and CRF receptor: Role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44: 525-557.
3. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, et al. (2003) International Union of Pharmacology. XXXVI. Current Status of the Nomenclature for Receptors for Corticotropin-Releasing Factor and Their Ligands. Pharmacol Rev 55: 21-26.
4. Farrokhi CB, Tovote P, Blanchard RJ, Blanchard DC, Litvin Y, et al. (2007) Cortagine: behavioral and autonomic function of the selective CRF receptor subtype 1 agonist. CNS Drug Rev 13: 423-443.
5. Leonard BE, (2005) The HPA and immune axes in stress: the involvement of the serotonergic system. Eur Psychiatry 20Suppl 3: S302-S306.
6. Stengel A, Taché Y, (2010) Corticotropin-releasing factor signaling and visceral response to stress. Exp Biol Med (Maywood) 235: 1168-1178.
7. Taché Y, Bonaz B, (2007) Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J Clin Invest 117: 33-40.
8. Larauche M, Mulak A, Taché Y, (2011) Stress-related alterations of visceral sensation: animal models for irritable bowel syndrome study. J Neurogastroenterol Motil 17: 213-234.
9. Taché Y, Brunnhuber S, (2008) From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases. Ann N Y Acad Sci 1148: 29-41.
10. Zorrilla EP, Heilig M, de Wit H, Shaham Y, (2013) Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend 128: 175-186.
11. Ising M, Zimmermann US, Kunzel HE, Uhr M, Foster AC, et al. (2007) High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 32: 1941-1949.
12. Sagami Y, Shimada Y, Tayama J, Nomura T, Satake M, et al. (2004) Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 53: 958-964.
13. Paez-Pereda M, Hausch F, Holsboer F, (2011) Corticotropin releasing factor receptor antagonists for major depressive disorder. Expert Opin Investig Drugs 20: 519-535.
14. Hubbard CS, Labus JS, Bueller J, Stains J, Suyenobu B, et al. (2011) Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. J Neurosci 31: 12491-12500.
15. Sweetser S, Camilleri M, Linker Nord SJ, Burton DD, Castenada L, et al. (2009) Do Corticotropin Releasing Factor-1 Receptors Influence Colonic Transit and Bowel Function in Females with Irritable Bowel Syndrome? Am J Physiol Gastrointest Liver Physiol. 296: G1299-306.
16. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, et al. (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34: 171-181.
17. Bailey JE, Papadopoulos A, Diaper A, Phillips S, Schmidt M, et al. (2011) Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. J Psychopharmacol 25: 1199-1206.
18. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, et al. (2008) A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165: 617-620.
19. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, et al. (2010) Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 27: 417-425.
20. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, et al. (1996) CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci U S A 93: 10477-10482.
21. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, et al. (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4- methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301: 333-345.
22. Kehne J, De Lombaert S, (2002) Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr Drug Targets CNS Neurol Disord 1: 467-493.
23. Chen C, (2006) Recent advances in small molecule antagonists of the corticotropin-releasing factor type-1 receptor-focus on pharmacology and pharmacokinetics. Curr Med Chem 13: 1261-1282.
24. Hodgetts KJ, Ge P, Yoon T, De Lombaert S, Brodbeck R, et al. (2011) Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyra zin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist. J Med Chem 54: 4187-4206.
25. Yoon T, Ge P, Delombaert S, Horvath R (3-4-2004) 5-substituted-2-arylpyrazines as modulators of CRF receptors. Patent: International Application Published Under The Patent Operation Treaty (PCT). 127 p.
26. Saunders PR, Maillot C, Million M, Taché' Y, (2002) Peripheral corticotropin-releasing factor induces diarrhea in rats: role of CRF1 receptor in fecal watery excretion. Eur J Pharmacol 435: 231-235.
27. Taché Y, Martinez V, Wang L, Million M, (2004) CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br J Pharmacol 141: 1321-1330.
28. Martinez V, Taché Y, (2001) Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats. Brain Res 893: 29-35.
29. Million M, Maillot C, Adelson DW, Nozu T, Gauthier A, et al. (2005) Peripheral injection of sauvagine prevents repeated colorectal distention-induced visceral pain in female rats. Peptides 26: 1188-1195.
30. Seymour PA, Schmidt AW, Schulz DW, (2003) The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev 9: 57-96.
31. Maillot C, Million M, Wei JY, Gauthier A, Taché Y, (2000) Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats. Gastroenterology 119: 1569-1579.
32. Martinez V, Rivier J, Wang L, Taché Y, (1997) Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function. J Pharmacol Exp Ther 280: 754-760.
33. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Orlando: Academic Press. 116 p.
34. Million M, Grigoriadis DE, Sullivan S, Crowe PD, McRoberts JA, et al. (2003) A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats. Brain Res 985: 32-42.
35. Bonaz B, Taché Y, (1994) Water-avoidance stress-induced c-fos expression in the rat brain and stimulation of fecal output: role of corticotropin-releasing factor. Brain Res 641: 21-28.
36. Ness TJ, Gebhart GF, (1988) Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudoaffective reflexes in the rat. Brain Res 450: 153-169.
37. Million M, Wang L, Wang Y, Adelson DW, Yuan PQ, et al. (2006) CRF2 receptor activation prevents colorectal distension-induced visceral pain and spinal ERK1/2 phosphorylation in rats. Gut 55: 172-181.
38. Coutinho SV, Plotsky PM, Sablad M, Miller JC, Zhou H, et al. (2002) Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat. Am J Physiol Gastrointest Liver Physiol 282: G307-G316.
39. Miampamba M, Maillot C, Million M, Taché Y, (2002) Peripheral CRF activates myenteric neurons in the proximal colon through CRF1 receptor in conscious rats. Am J Physiol Gastrointest Liver Physiol 282: G857-G865.
40. Williams CL, Peterson JM, Villar RG, Burks TF, (1987) Corticotropin-releasing factor directly mediates colonic responses to stress. Am J Physiol 253: G582-G586.
41. Ataka K, Kuge T, Fujino K, Takahashi T, Fujimiya M, (2007) Wood creosote prevents CRF-induced motility via 5-HT3 receptors in proximal and 5-HT4 receptors in distal colon in rats. Auton Neurosci 133: 136-145.
42. Kehne JH, Cain CK, (2010) Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. Pharmacol Ther 128: 460-487.
43. Stengel A, Taché Y, (2009) Neuroendocrine control of the gut during stress: corticotropin-releasing factor signaling pathways in the spotlight. Annu Rev Physiol 71: 219-239.
44. Kimura T, Amano T, Uehara H, Ariga H, Ishida T, et al. (2007) Urocortin I is present in the enteric nervous system and exerts an excitatory effect via cholinergic and serotonergic pathways in the rat colon. Am J Physiol Gastrointest Liver Physiol 293: G903-G910.
45. Overman EL, Rivier JE, Moeser AJ, (2012) CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-alpha. PLoS One 7: e39935.
46. Gulyas J, Rivier C, Perrin M, Koerber SC, Sutton S, et al. (1995) Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci USA 92: 10575-10579.
47. Larauche M, Gourcerol G, Wang L, Pambukchian K, Brunnhuber S, et al. (2009) Cortagine, a CRF1 agonist, induces stress-like alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways. Am J Physiol Gastrointest Liver Physiol 297: G215-G227.
48. Taché Y, Million M (2006) Central corticotropin-releasing factor and the hypothalamic-pituitary-adrenal axis in gastrointestinal physiology. In: Johnson LR, Wood J, editors. Physiology of the Gastrointestinal Tract. Academic Press. 791-816.
49. Martinez V, Taché Y, (2006) CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des 12: 1-18.
50. Gué M, Del Rio-Lacheze C, Eutamene H, Theodorou V, Fioramonti J, et al. (1997) Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil 9: 271-279.
51. Greenwood-Van Meerveld B, Johnson AC, Cochrane S, Schulkin J, Myers DA, (2005) Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats. Neurogastroenterol Motil 17: 415-422.
52. Schwetz I, McRoberts JA, Coutinho SV, Bradesi S, Gale G, et al. (2005) Corticotropin-releasing factor receptor 1 mediates acute and delayed stress-induced visceral hyperalgesia in maternally separated Long-Evans rats. Am J Physiol Gastrointest Liver Physiol 289: G704-G712.
53. Larauche MH, Bradesi S, Million M, McLean P, Taché YF, et al. (2008) Corticotropin releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats. Am J Physiol Gastrointest Liver Physiol. 294: G1033-40.
54. Gaudreau GA, Plourde V, (2004) Involvement of N-methyl-d-aspartate (NMDA) receptors in a rat model of visceral hypersensitivity. Behav Brain Res 150: 185-189.
55. Larsson M, Arvidsson S, Ekman C, Bayati A, (2003) A model for chronic quantitative studies of colorectal sensitivity using balloon distension in conscious mice - effects of opioid receptor agonists. Neurogastroenterol Motil 15: 371-381.
56. Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, et al. (2002) Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 122: 1771-1777.
57. Munakata J, Naliboff B, Harraf F, Kodner A, Lembo T, et al. (1997) Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 112: 55-63.
58. Million M, Wang L, Adelson DW, Roman F, Diop L, et al. (2007) Pregabalin decreases visceral pain and prevents spinal neuronal activation in rats. Gut 56: 1482-1484.
59. Hu HJ, Gereau RW, (2003) ERK integrates PKA and PKC signaling in superficial dorsal horn neurons. II. Modulation of neuronal excitability. J Neurophysiol 2003 Sep; 90 (3): 1680-8 Epub 2003 May 15 90: 1680-1688.
60. Sengupta JN (2009) Visceral pain: the neurophysiological mechanism. Handb Exp Pharmacol 31-74.
61. Zorrilla EP, Koob GF, (2010) Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 15: 371-383.
62. Zmijewski MA, Slominski AT, (2010) Emerging role of alternative splicing of CRF1 receptor in CRF signaling. Acta Biochim Pol 57: 1-13.
63. Fleck BA, Hoare SR, Pick RR, Bradbury MJ, Grigoriadis DE, (2012) Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. J Pharmacol Exp Ther 341: 518-531.